pre-IPO PHARMA

COMPANY OVERVIEW

AffaMed Therapeutics is a biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmic, neurological and psychiatric disorders for patients in Greater China and around the world. The leadership team of AffaMed Therapeutics has gained deep industry expertise and an extensive track record in high-quality clinical development, regulatory affairs, CMC, business development and commercial operations at leading multi-national pharmaceutical companies in China and globally.


LOCATION

  • Shanghai, None, China
  • Beijing, None, China
  • New York, NY, USA

  • THERAPEUTIC AREAS

  • Neurodegenerative Disease
  • Neurological Disorders
  • Ophthalmology

  • WEBSITE

    https://www.affamed.com/


    CAREER WEBSITE

    https://www.affamed.com/careers


    SOCIAL MEDIA


    INVESTORS

    cbc-group fountainhead-partners lake-bleu-capital orion-science-capital partners-investment superstring-capital


    PRESS RELEASES


    Sep 25, 2023

    AffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib (Luminate) First-in-Class Candidate for the Treatment of Intermediate Dry AMD USA - English APAC - English


    Sep 20, 2023

    AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery USA - English APAC - English


    Aug 10, 2023

    AffaMed Therapeutics Announces Partner Vistagen Reports Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder USA - English APAC - English


    May 31, 2023

    AffaMed Therapeutics Announces Completion of Patient Enrollment in the Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA in Cataract Surgery Patients USA - English APAC - English


    May 25, 2023

    AffaMed Therapeutics Announces Partner Allgenesis Reports Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema USA - English APAC - English


    For More Press Releases


    Google Analytics Alternative